A Single Dose Clinical Trial to Study the Safety of ART-I02 in Patients With Rheumatoid Arthritis

Trial Profile

A Single Dose Clinical Trial to Study the Safety of ART-I02 in Patients With Rheumatoid Arthritis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs ART I02 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Arthrogen
  • Most Recent Events

    • 27 Jun 2017 Planned number of patients changed from 15 to 12.
    • 27 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 16 Feb 2017 Results from this trial are expected by the end of 2018, according to an Arthrogen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top